Lilly recasts retatrutide and Foundayo as cardiometabolic franchise
Yahoo Finance reports the company is repositioning its obesity pipeline around broader cardiometabolic outcomes rather than weight loss alone.
MH
By Maren Holt · Senior Reporter, GLP-1
Jun 8 03:00 ETSource: Yahoo Finance
The wire
- 01Eli Lilly's latest obesity results are being framed around retatrutide and Foundayo as part of a wider cardiometabolic story, according to Yahoo Finance.
- 02Retatrutide is the most watched triple agonist on the incretin pipeline, and a cardiometabolic positioning affects likely label breadth and payer coverage.
- 03The item is market commentary; specific trial endpoints, doses and timelines were not detailed.
From the source
Read at finance.yahoo.comEli Lilly Obesity Wins Recast Retatrutide And Foundayo As Cardiometabolic Story
